Home » Merck VBF Program Named 2012 Facility of the Year Awards Overall Winner
Merck VBF Program Named 2012 Facility of the Year Awards Overall Winner
ISPE announced during the Plenary Session at its 2012 Annual Meeting in San Francisco, Calif., that Merck’s Vaccine Bulk Manufacturing Facility (VBF) Program of Projects is the Overall Winner of the 2012 Facility of the Year Awards (FOYA) program.
Faced with a projected production shortfall for the Varicella product franchise, Merck responded by delivering the Vaccine Bulk Manufacturing Facility (VBF) Program of Projects in Durham, North Carolina, USA. The 214,000-square-foot facility was built in record time and doubled the output of the vaccine used for Chicken Pox and Shingles.
The Merck Team used an innovative hybrid modular construction strategy that maximized off-site fabrication and equipment testing. Interesting for this application, the integrated construction execution strategy decoupled the design and construction of the building envelope and shell from interior process components, enabling parallel processes – as soon as the building shell was dried in and elevated slab poured, modules were installed simultaneously above the slab. This resulted in the ability to establish two independent work zones (above and below the slab) and saved five months on the schedule.
The team was organized as “One Team” with all members co-located in an integrated partnership. LEAN Six Sigma principles were used throughout the project and resulted in an accelerated transfer of systems to operations. Integrating more than 200 lessons learned from the existing facility and process, the facility was delivered 40% faster than industry benchmarks. For this, Merck was named the 2012 Facility of the Year Awards Overall Winner.
More information about Merck’s winning project, as well as the Facility of the Year Awards program in general, can be found at www.FacilityoftheYear.org.
Merck Stops Development of Parkinsonís DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesnít work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »